Publicly Traded Botanical Therapeutics® Company Blends Eastern, Western Approaches to Wellness and Medical Treatment
Herborium Group Combines Science and
Nature to Create and Market New
FORT LEE, N.J. — Herborium Group, Inc., a small, publicly tradedBotanical Therapeutics® company, has an ambitious agenda: to bridge the gap between Eastern and Western approaches to medicine and enable consumers to benefit from the best of both worlds as they seek wellness. The company is uniquely positioned to deliver on its promise, combining the focus on science and metrics predominant in Western medicine with an emphasis on natural, botanical ingredients and a more holistic view of wellness favored in traditional Chinese medicine and other so-called “alternative” medical approaches. The company’s founder, Dr. Agnes P. Olszewski, CEO and Chairwoman for Herborium Group, believes — with good reason — that the time is right to merge Eastern and Western sensibilities for the benefit of all.
“Our view is that modern Western medicine and herbal treatments — from China and elsewhere — both have much to offer,” said Dr. Olszewski. “What makes Herborium unique is that we combine science and nature to create Botanical Therapeutics®, and we attempt to teach consumers and anyone willing to learn about the benefits — and possible drawbacks — of natural medicine. We try to provide information on both — the pitfalls and the possibilities of herbal medicinal products and favor a complementary and inclusive rather than an exclusive approach. Our products are proprietary compounds that have been researched and tested. We believe that the time is right for this approach.”
Timing is an important element of Herborium’s current strategy: Dr. Olszewski originally explored the idea in 2002, but now she sees that the timing might not have been ideal a decade ago. In the interim, many developments have taken place that make a successful fusion of a number of elements of Eastern and Western medicinal approaches more likely, including:
- Use of the Internet as a tool for patients to learn more about alternative treatment options, including natural remedies and their scientific bases.
- Food and Drug Administration (FDA) issuance of draft guidelines on clinical testing for the botanical drug industry (Guidance for Industry on Botanical Drug Products, June 9th, 2004).
- Growing acceptance of natural and traditional approaches to wellness, exemplified by exploration of herbal treatments by global pharmaceutical firms in the past decade.
- Increasing globalization and cross-cultural influences, which led many to conclude that diverse approaches to treatment of a number of health concerns and to wellness can be both complementary and beneficial.
With deep expertise in the global pharmaceutical industry and a solid grounding in both Eastern and Western business cultures and traditions, Dr. Olszewski is singularly qualified to lead a company at the forefront of an evolution toward a hybrid approach to health and wellness. Dr. Olszewski has worked extensively in China, leading consulting engagements for major pharmaceutical companies and developing the network of relationships that are the foundation of any successful business venture in China.
Dr. Olszewski also has a deep understanding of the European approach to complementary medicine, which blends natural medicine and classic Western (chemical) methods much more frequently than in the U.S. Germany has the highest consumption per capita of herbal medicinal products in Europe, with France and the United Kingdom ranked closely behind it. In addition, Germany is a leader in developing advanced agricultural practices and standards to grow, harvest and process medicinal herbs and plants, with other European countries following suit. Dr. Olszewski’s familiarity with the methods favored in Europe add to her acumen on the topic of herbal medicinal products.
While advising clients on a pharmaceutical joint venture, Dr. Olszewski became intrigued by the concept of “green gold” — Traditional Chinese Medicine (TCM) that has a 5,000-year track record and thus provides new product developers with a treasure trove of possibilities. Putting together a network of experts in China and the U.S., Dr. Olszewski explored promising compounds, leading to the development of the conceptual foundation for Herborium and an introduction of Herborium first (flagship) product, AcnEase®,an all-botanical ingredients-based product with an effectiveness rate of up to 95% for the treatment of acne and controlling symptoms of rosacea. The product, which has been both scientifically and market tested, succeeds by treating the causes of acne, not just the symptoms.
currently developing other Botanical Therapeutics® that will address sexual health issues in men and women, energy
and stress, symptoms of BPH (benign prostate hyperplasia) and other health
concerns. Herborium will continue to operate at the intersection of nature and
science, developing unique Botanical Therapeutics® that fuse Eastern and
Western approaches to give patients the best of both worlds. To find out more
about Herborium, please visit http://www.herborium.com.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical-based medicinal products to consumers and healthcare professionals. The company uses clinical validation to establish and maintain a differential advantage. The company sells its products in the U.S. and Europe. For more information, please visit www.herborium.com and www.acnease.com.